All In Biotech

Drug Trial Radar · NCT07449299

Rct Assessing Pregnancy - Piroxicam for Ec With Levonorgestrel

Last checked: Nov 19, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 1,458 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,458

Planned (sponsor's estimate)

Start

Mar 2027

Primary completion

Jun 2031

Study completion Nov 2031

Sponsor

Lead sponsor
University of UtahAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 16 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized controlled trial will test oral levonorgestrel + piroxicam vs. levonorgestrel + placebo for emergency contraception in a representative U.S. population that has higher pregnancy risk than in the prior study because of higher weights, different intercourse patterns, and different clinic accessibility. Data from this project will inform clinical practice in the U.S. and beyond for those desiring the most effective method of emergency contraception pills.

Conditions

  • Emergency Contraception
  • Contraception
  • COX-2 Inhibitor

Interventions

  • Levonorgestrel 1.5 mg and Piroxicam 40 mgDrug

    The study intervention is a combination of Levonorgestrel 1.5 mg and Piroxicam 40 mg for emergency contraception. Participants will be randomized 3:1 to this vs. Levonorgestrel 1.5 mg and placebo.

  • Oral LNG + PlaceboDrug

    The study intervention is a combination of Levonorgestrel 1.5 mg and placebo for emergency contraception. Participants will be randomized 3:1 to Levonorgestrel 1.5 mg and Piroxicam vs. this option.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. EC efficacy between the two study groups measured by pregnancy status four weeks after EC use.Time frame: One month after consuming study drug

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.